Resumo
Definição
História e exame físico
Principais fatores diagnósticos
- fever/chills
- night sweats, malaise, fatigue, anorexia, weight loss, myalgias
- weakness
- arthralgias
- headache
- shortness of breath
- meningeal signs
- cardiac murmur
- Janeway lesions
- Osler nodes
- Roth spots
Outros fatores diagnósticos
- splinter hemorrhages
- cutaneous infarcts
- chest pain
- back pain
- palatal petechiae
Fatores de risco
- prior history of infectious endocarditis
- presence of artificial prosthetic heart valves
- certain types of congenital heart disease
- postheart transplant (patients who develop a cardiac valvulopathy)
- immunocompromised state
- presence of cardiac implanted electronic device or intravascular catheters (e.g., for hemodialysis)
- acquired degenerative valve disease
- mitral valve prolapse or bicuspid valve prolapse
- hypertrophic cardiomyopathy
- intravenous drug use
- chronic Q fever
Investigações diagnósticas
Primeiras investigações a serem solicitadas
- blood cultures
- echocardiogram
- CBC
- CRP
- serum chemistry panel with glucose
- LFTs
- urinalysis
- ECG
Investigações a serem consideradas
- rheumatoid factor
- erythrocyte sedimentation rate
- complement levels
- cardiac CT
- MRI
- nuclear imaging and PET
- specific tests for blood culture-negative endocarditis
Novos exames
- mean platelet volume (MPV)
- anti‐beta-2‐glycoprotein I antibodies
- D-dimer and troponin I
Algoritmo de tratamento
suspected infective endocarditis
native valve: confirmed endocarditis
prosthetic valve: confirmed endocarditis
at high risk of infective endocarditis
Colaboradores
Consultores especialistas
Carl Zehner, MD
Assistant Professor of Medicine
University of Texas MD Anderson Cancer Center
Department of Cardiology
Houston
TX
Declarações
CZ declares that he has no competing interests.
Agradecimentos
Dr Carl Zehner would like to gratefully acknowledge Dr Ammara Mushtuq, Dr Tracey Keteepe-Arachi, Dr Aneil Malhotra, Dr Michael Papadakis, Professor Sanjay Sharma, Dr Jason C. Schultz, Dr Nisha K. Lassi, and Dr Nandan S. Anavekar, previous contributors to this topic.
Declarações
TKA, MP, SS, JCS, NKL, and NSA declare that they have no competing interests. AMu declares that she is Principal Investigator on a grant from Merck on ceftolozane-tazobactam, writer for the Lancet family of journals, question writer for Blueprint Test preparations, and a peer-reviewer for Clinical Overviews, Elsevier (topics influenza and HIV). AMa is an author of a number of references cited in this topic.
Revisores
Vandana Desai, MD
Professor of Pediatrics
SMIMER Hospital
Gujarat
India
Declarações
VD declares that she has no competing interests.
Lucieni Oliveira Conterno, MD, PhD
Director
Clinical Epidemiology Unit
Marilia Medical School
Sao Paulo
Brazil
Declarações
LOC declares that she has no competing interests.
Andrew Wang, MD
Associate Professor of Medicine
Director, Cardiovascular Disease Fellowship Program
Duke University Medical Center
Durham
NC
Declarações
AW declares that he has no competing interests.
Créditos aos pareceristas
Os tópicos do BMJ Best Practice são constantemente atualizados, seguindo os desenvolvimentos das evidências e das diretrizes. Os pareceristas aqui listados revisaram o conteúdo pelo menos uma vez durante a história do tópico.
Declarações
As afiliações e declarações dos pareceristas referem--se ao momento da revisão.
Referências
Principais artigos
Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015 Oct 13;132(15):1435-86.Texto completo Resumo
Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042.Texto completo Resumo
Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2021 Feb 2;143(5):e72-227.Texto completo Resumo
Wilson WR, Gewitz M, Lockhart PB, et al. Prevention of viridans group streptococcal infective endocarditis: a scientific statement from the American Heart Association. Circulation. 2021 May 18;143(20):e963-78.Texto completo Resumo
Artigos de referência
Uma lista completa das fontes referenciadas neste tópico está disponível para os usuários com acesso total ao BMJ Best Practice.

Diagnósticos diferenciais
- Rheumatic fever
- Atrial myxoma
- Libman-Sacks endocarditis
Mais Diagnósticos diferenciaisGuidelines
- Blood culture-negative endocarditis
- 2023 ESC guidelines for the management of endocarditis
Mais DiretrizesVideos
Venepuncture and phlebotomy: animated demonstration
How to perform an ECG: animated demonstration
More videosPatient information
Endocarditis
More Patient informationLog in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer
